ERN1 and neoplasm: Hence, to promote CD95L-induced cell death over non-apoptotic cellular outcomes, it will also be required to define tumour contexts in which additional cell death checkpoints (e.g., mediated by IAPs) should be alleviated in concert with IRE1 inhibition.